Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07779031 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

Name: A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT — clinical trial record (NCT07779031)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TP53

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorLiping Dou

Started2025-05-01

View on ClinicalTrials.gov ↗

To explore the safety and efficacy of selinexor combined with azacitidine as post-transplant maintenance therapy for TP53-mutated AML/MDS.

Trial Details

NCT Number	NCT07779031
Lead Sponsor	Liping Dou
Conditions	Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
Enrollment	58 participants
Start Date	2025-05-01
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-21